Zhengye Biotechnology Holding (ZYBT) Current Deferred Revenue (2023 - 2024)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Zhengye Biotechnology Holding (ZYBT) has disclosed Current Deferred Revenue for 2 consecutive years, with $485166.8 as the latest value for Q4 2024.

• Quarterly Current Deferred Revenue fell 24.08% to $485166.8 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $485166.8 through Dec 2024, down 24.08% year-over-year, with the annual reading at $477000.0 for FY2024, 26.73% down from the prior year.
• Current Deferred Revenue for Q4 2024 was $485166.8 at Zhengye Biotechnology Holding, down from $639020.9 in the prior quarter.
• The five-year high for Current Deferred Revenue was $639020.9 in Q4 2023, with the low at $485166.8 in Q4 2024.

Peer Comparison